Bluestar Adisseo Company

General Assembly of Shareholders for FY2017

Meeting Materials

17 April 2018

Bluestar Adisseo Company

Agenda for the Annual Meeting of Shareholders for FY2017

Time of On-site Meeting: 25 April 2018 (Wednesday) 14:30 p.m.

Venue: meeting room in Bluestar Building, 9 Beituchengxi Road, Chaoyang District, Beijing

Host: Gerard Deman, the Chairman of Adisseo

Attendee:

1. Shareholders holding the Company's shares on the record day
   The record day for the shareholders' meeting is 18 April 2018. Shareholders who are registered in book by China Securities Depository and Clearing Corporation Limited (CSDC) Shanghai Division after the trading market is closed on the record day are entitled to attend the shareholders' meeting. They may also appoint proxies in writing to attend and vote. The proxies can be non-shareholders.
2. Directors, supervisors and senior management
3. Lawyers engaged by the Company

Agenda

I. The host launches the meeting with welcome speech.

II. The Board Secretary delivers the voting rules and highlights.

III. Electing vote counters and scrutineer.

IV. Attendees deliberate and discuss the following proposals:

1. Proposal on 2017 Annual Report and the Executive Summary (see Material 1 for details)

2. Proposal on 2017 Annual Final Accounts (see Material 2 for details)

3. Proposal on Board's Report for FY2017 (see Material 3 for details)
4. Proposal on Board of Supervisors' Report for FY2017 (see Material 4 for details)
5. Proposal on 2017 Annual Plan of Dividends Distribution (see Material 5 for details)
6. Proposal on Appointment of Auditor and Internal Control Auditor for the Year 2018 (see Material 6 for details)
7. Proposal on Renewal of D&O Insurance Policy (see Material 7 for details)
8. Proposal on Approval of Renewal of Finance Service Agreement between ChemChina Finance Co., Ltd. & Bluestar Adisseo Company (see Material 8 for details)

V. Listening to Independent Directors' Report for FY2017

VI. Q&A Session for Shareholders.

VII. Shareholders vote.

VIII. Votes cast on-site are counted and announced.

IX. Break and combing online and on-site voting results.

X. The results of voting are announced.

XI. Lawyers read the legal opinion.

XII. Directors, supervisors and the board secretary sign.

XIII. The meeting ends.

Bluestar Adisseo Company

Annual Meeting of Shareholders for FY2017

Notes on the Meeting

I. The Office of the Board Secretary is in charge of organization of the meeting and handling relevant matters.

II. The board of directors protects legitimate benefits and rights of shareholders in the principle of ensuring the order and efficiency of the meeting as well as exercising its legal duties and responsibilities.

III. Shareholders attending the meeting have legal rights of speaking, inquiring and voting, etc.

IV. Shareholders shall register with the Office of the Board Secretary before speaking in the shareholders' meeting. The total time of shareholders' speeches shall generally be limited to 30 minutes. In case more than one shareholder asks to speak, the host shall arrange the sequence of speaking in terms of shareholding, where shareholder with most shares speaks first. Shareholder shall report its shareholding before speaking. Generally each shareholder shall not speak for longer than 5 minutes.

V. To enhance the efficiency of the meeting, after the ending of shareholders' speeches related to the proposals, the voting shall begin immediately. The registration of the meeting closes before the voting.

VI. The meeting adopts both on-site voting and online voting.

VII. Shareholders attending the shareholders' general meeting shall exercise their legal obligations seriously. They shall not violate other shareholders' rights and benefits, neither shall they disturb the order of the meeting.

Bluestar Adisseo Company
Board Secretary Office

Material 1

Proposal on 2017 Annual Report and the Executive Summary

Dear Shareholders,

In compliance with *the Contents and Formats of Information Disclosure by Companies Offering Securities to the Public No. 2 - Contents and Formats of Annual Reports (2017 Revision)* issued by China Securities Regulatory Commission ("CSRC") and *Shanghai Stock Exchange Listing Rules (2014 Revision)*, etc., the board of directors of Bluestar Adisseo Company (the "Company"), deliberated and passed the Company's 2017 Annual Report and the Summary Version. Kindly find 2017 Annual Report and the Executive Summary released on 21 March 2018 on *China Securities Journal, Shanghai Securities News* and the official website of Shanghai Stock Exchange (www.sse.com.cn).

Please review the above proposal.

Material 2

Proposal on 2017 Annual Final Accounts

Dear Shareholders,

2017 Annual Final Accounts contain the balance sheet, the statement of income, the statement of cash flows and the statement of owners' equity, etc., as of 31 December 2017. KPMG Huazhen LLP has audited such documents and issued an unqualified audit opinion. For details please kindly find in *Audit Report for FY2017 and Audited Financial Statements* and "Section 11 Financial Statements" of *2017 Annual Report* released on 21 March 2018 on *China Securities Journal*, *Shanghai Securities News* and the official website of Shanghai Stock Exchange (www.sse.com.cn).

Please review the above proposal.

Material 3

Proposal on Board's Report for FY2017

Dear Shareholders,

During the year of 2017, the Company's board carried out the development policy steadily and proactively to strengthen the management of operation in all aspects. The board accomplished the major operation tasks of this year soundly. For the Company's development in the year of 2018 and in the future, the board will continue to focus on major direction. For details of summary, development strategy and the business plan, please kindly see attached the Board's Report for FY2017.

Please review the above proposal.

Attachment: Board's Report for FY2017

2017 Annual Report by Board of Directors

1. The board of directors discussion and analysis of the company's operations during the reporting period

1.1. Discussion and analysis of the operation

Adisseo's businesses focus on research, development, production and sale of feed additives for animal nutrition. Its main products are classified within 3 categories of products: Performance products, Specialty products, and Other Products for other animal feed additives.

Its performance, financial position and future are affected by the global macro economy. Although the global macro economy has demonstrated signs of slow recovery, significant disparity exists among the recovery process for each competitor. Debt crisis, trade imbalances and exchange rate fluctuations also increase the uncertainty of such recovery. Thanks to that fact that Adisseo is a key important player in the food value chain, Adisseo has high resilience in facing with those uncertainties, which can be proved by the stable profit generation in the past 10 years.

Adisseo faces competition from large and well-known companies with strong financial positions as well as competition from smaller companies in the regional or local markets. Chinese New Comers (CUC / NHU) have started their new units during the years 2016-2017. All Historical players have communicated about new facilities to come during the period 2018-2021 (Sumitomo, Evonik, Novus and Adisseo). CJ is advancing with their objective to diversify towards more competitive raw material sources, as its production process is partially independent from petroleum based raw materials.

Adisseo has taken steps to improve its competitiveness, including tightening cost control, improving production technologies, increasing its production capacity, providing value-added services and enriching product portfolio:

- European platform expansion project: it should add 50 KT of production capacity on the European plants by adding a new complete production line in downstream unit (Burgos) and in upstream unit (Les Roches), and some adjustments in existing intermediate products units. It is progressing within budget and on the schedule. It is expected to be completed by the end of 2018;
- Launch of Rhodimet® A-Dry+: in 2017 Adisseo also finalized the development of this truly innovative product. It is a brand new powder methionine product, based on the liquid methionine ("HMTBA") technology in order to offer the advantages of this molecule to customers whose manufacturing process does not allow the use of liquid form. This innovative product is expected to be commercialized during 2018. The new A-Dry+ production unit, about 9 KT capacity, is under construction at the Burgos plant, consolidating the long-term future of the site;
- Approval of the construction of a new platform: to meet the continuously growing demand of customers and thus consolidate its leadership role, the construction project of a new

liquid methionine plant with a capacity of 180 KT per year was approved in January 2018. The new facility will be located in the Nanjing Liuhe Chemical Park, adjacent to the existing Adisseo plant in Nanjing. The commissioning of this new platform is expected for mid-2021;

- Specialty products are under active development as a second business-pillar to enhance animal performance and health. The Company sees great growth potential in Specialty products and actively explores innovative products. Adisseo also acquired Nutriad in December 2017: Nutriad's product range, the species addressed, and its target markets are highly complementary to Adisseo's and will allow to implement integrated solutions to offer even more value to customers.

2017 results

In (100 million) Yuan	**2017**	**2016**	**Change (%)**
Operating revenue	104.0	106.9	-3%
Net cash flow arising from operating activities	25.1	30.5	-18%
Net profit attributable to shareholders	13.2	18.7	-29%
Net profit attributable to the shareholders of the Company after deduction of non-recurring profit or losses	13.0	18.7	-31%
Basic earnings per share (Yuan/ share)	0.49	0.70	-30%

Adisseo outdated its safety objectives in 2017 with the accident with or without lost time injury frequency rate of 0.37, compared to a goal of 0.48 (TRIR or Total Recordable Injuries Rate – number of accidents per 200,000 hours worked). This result is one of the best in the industry. It is the consequence of the Safety action plans continuously reinforced to reach our objective: zero accident.

2017 business trends are above expectations and reflect the combined impacts of:

- All product lines has obtained steady volume growth in 2017;
- Unfavorable economic environment with weaker US$ and higher energy & raw material costs;
- In Methionine business, a less favorable market environment as expected with a significant decrease in the selling price. The Company's revenue remains flat thanks to a high sales volume growth of methionine by 11% on average, of which liquid methionine's growth rate is even higher, versus a global methionine demand growing by 6% already;
- A rigorous cost control and plant's management that ensure a good level of profit margin in a context of a decreasing pricing on methionine;
- Rigorous cost management, pricing tactic, proactive purchasing management, including management of a global Vitamin A short supply, initiated by the accidental shutdown of

the unit of our n°1 intermediate supplier that enable Vitamin business also achieve very good results in 2017;

- Innovation and marketing efforts launched years ago in Specialty business that let Adisseo record another year of strong growth 27% in 2017 compared with 2016;
- New specialty products launches at a space of one per year over the last 4 years. The increase in operating revenue in Specialty products reflects Adisseo's constant innovation and the success of new products. During 2017, Adisseo pursued the development of the last products launched Selisseo® in 2014, Rovabio Advance® in 2015 and Alterion® in 2016, mainly thanks to registration in untapped markets.

Due to these factors, 2017 net profit attributable to shareholders is above budget.

2018 outlook

- Safety is Adisseo first priority. In 2018, it will pursue its zero accident objective and further improve its safety performance;
- Adisseo will also focus on environmental impacts. The development and implementation of action plans for each entity of the Group will contribute to reduce environmental impacts (notably waste discharge, water consumption and air quality);
- Demand for methionine will continue to grow on a global basis at a rate of around 6.0% per year. Adisseo objective is to maintain its global leadership and market share by better capturing growth from the methionine market (liquid and powder forms) and remaining flexible at serving customers' needs. The leadership of Adisseo in the methionine industry is expected to be further strengthened with the launch of Rhodimet® A-Dry+ as well as the completion of capacity expansion on the European sites in 2018 with European platform expansion project. The newly announced investment of a 180 KT liquid methionine plant in Nanjing will enable Adisseo to meet ever-increasing customer needs and to achieve cost efficiency in the near future. It is also a key step to consolidate the Company's leadership;
- Proactive price management of Performance products will be key to achieve Adisseo's performance;
- On Specialties development, after the launch of Selisseo®, a Specialty product based on selenium in 2014, Advance®, a new enzyme product in 2015 and Alterion®, a new probiotic in 2016, Adisseo will continue to invest to develop with an objective to launch one new product on the market every year with a leverage effect thanks to the incubator Innov'L@b launched in 2017;
- The recent acquisition of Nutriad, a global feed additives producer, is part of Adisseo' strategy to become one of the worldwide leaders of feed specialty additives. Nutriad products range, the animal species addressed (poultry, swine, aquaculture, dairy and cattle), and its customers are highly complementary to Adisseo's and will allow the combined businesses to implement integrated solutions and to offer even more value to customers;
- Adisseo will continue to manage its Selling and General & Administrative (SG&A) expenses in all entities endeavoring to achieve better-than-expected results;
- US Dollar and raw material cost will still be key factors.

Leveraging on the dynamic of the last quarters in 2017 and its strategic initiatives, growth momentum in Q1 2018 sales is expected to remain strong.

1.2. Analysis of main changes in items of profit & loss statement and cash flow statement

Currency: RMB

Items	Amount of current period	Amount in the same period of last year	Change (%)
Operating revenue	10,397,823,108	10,688,263,140	-3%
Cost of sales	6,350,759,160	5,618,473,986	13%
Selling and distribution expenses	1,005,421,123	900,475,273	12%
General and administrative expenses	721,033,442	849,592,390	-15%
Financial expenses	(57,062,707)	(32,392,590)	-76%
Net cash flow from operating activities	2,513,085,624	3,053,923,615	-18%
Net cash flow from investing activities	(900,548,429)	(609,768,378)	-48%
Net cash flow from financing activities	(880,068,583)	(751,646,313)	-17%
Research and development expenditure	300,228,195	245,649,340	22%

1.3. Income and cost analysis

Analysis by industry, by product and by region

Unit: Yuan

Main Operations by industry						
By industry	Operating revenue	Cost of sales	Gross profit ratio (%)	Increase/de-crease in operating revenue on the same period of last year (%)	Increase/decrease in operating cost on the same period of last year (%)	Variation in GP ratio on the same period of last year
Health and Nutrition	10,397,823,108	6,350,759,160	39%	-3%	13%	-8%

Main operations by product						
By product	Operating revenue	Cost of sales	Gross profit ratio (%)	Increase/decrease in operating revenue on the same period of last year (%)	Increase/decrease in operating cost on the same period of last year (%)	Variation in GP ratio on the same period of last year
Performance products	8,101,555,708	5,290,143,748	35%	-7%	16%	-13%
Specialty products	1,729,578,118	757,693,985	56%	27%	11%	6%
Other products	566,689,282	302,921,427	47%	-5%	-17%	8%
Total	**10,397,823,108**	**6,350,759,160**	**39%**	**-3%**	**13%**	**-8%**

Main operations by region						
By region	Operating revenue	Cost of sales (*)	Gross profit ratio (%)	Increase/decrease in operating revenue on the same period of last year (%)	Increase/decrease in operating cost on the same period of last year (%)	Variation in GP ratio on the same period of last year
Europe / Africa/MO	3,305,841,954			-3%		
North & Central America	2,312,659,756			10%		
Asia / Pacific (excluded China)	1,709,651,123			-3%		
South America	1,642,983,410			-5%		
China	1,154,068,435			-18%		
Other	272,618,430			-10%		
Total	**10,397,823,108**			**-3%**		

(*) The Company discloses only operating revenue by region due to the fact that neither operating cost, nor gross margin are monitored by region.

Performance products are mainly driven by the methionine business. The decrease in operating revenue by 7% is due to the sharp decrease in methionine prices in 2017 compared to 2016. The negative price impact on methionine has been partly balanced by a very significant volume growth of 11%, especially on liquid methionine. Adding a negative US$/€ and raw material purchasing price impact, gross profit ratio decreased but still maintained at a quite solid level.

Operating revenue in Specialty products is significantly increasing with 27% annual growth rate. Adisseo confirms its leadership in the Ruminants segment with 2017 volumes recovery after 2016 milk crisis especially with 50% of volume increase is Smartamine®. Enzymes also delivered a double digit growth thanks to the successful innovation in a fierce competitive environment. Selisseo® and Alterion®, products launched in recent years, more than almost double their operating revenue compared to last year, confirming Adisseo ability to successfully leverage on its innovation investments. This revenue increase allowed a gross profit improvement.

Cost of sales suffered from raw material prices increase partly balanced by rigorous cost management.

Analysis of the factors impacting the income from sale of products

Unit: Yuan

In comparison with 2016	Change in Volume	Change in sales price	Exchange rate impact
Performance products	819,262,312	(1,854,230,666)	402,366,152
Specialty products	367,581,202	(16,787,551)	21,774,781

Adisseo's operating revenue in 2017 totaled RMB 10,397,823,108 and decreased by 6% at constant EUR/CNY rate (i.e. -3% at current EUR/CNY rate), compared to 2016.

Cost analysis table

Unit: Yuan

By industry							
By industry	Cost composition items	Amount of current period	Proportion to the total cost of current period (%)	Amount of the same period of last year	Proportion to the total cost of the same period of last year (%)	Proportion of change in the amount of current period over the same period of last year (%)	Explanation

Health and Nutrition		6,350,759,160	100%	5,618,473,986	100%	13%	Unfavorable impact of increasing volume of sales and high raw material cost

By product							
By product	Cost composition items	Amount of current period	Proportion to the total cost of current period (%)	Amount of the same period of last year	Proportion to the total cost of the same period of last year (%)	Proportion of change in the amount of current period over the same period of last year (%)	Explanation
Performance products	Raw materials, purchased equipment and consumables used (71%), Depreciation and amortization (11%), Other (18%)	5,290,143,748	83%	4,568,963,128	81%	16%	Unfavorable impact of increasing volume of sales and high raw material cost

By product							
By product	Cost composition items	Amount of current period	Proportion to the total cost of current period (%)	Amount of the same period of last year	Proportion to the total cost of the same period of last year (%)	Proportion of change in the amount of current period over the same period of last year (%)	Explanation
Specialty products	Raw materials, purchased equipment and consumables used (81%), Depreciation and amortization (4%), Other (15%)	757,693,985	12%	684,284,187	12%	11%	Unfavorable impact of increasing volume of sales
Other products	Raw materials, purchased equipment and consumables used (43%), Depreciation and amortization (17%), Other (40%)	302,921,427	5%	365,226,671	7%	-17%	Favorable impact of decreasing volume of sales

1.4. Expenses

Unit: Yuan

Items	Amount of current period	Amount in the same period of last year	Change (%)
Selling and distribution expenses	1,005,421,123	900,475,273	12%
General and administrative expenses	721,033,442	849,592,390	-15%
Financial (income)/expenses	(57,062,707)	(32,392,590)	76%

The increase of selling expenses was in line with the increase of sales volumes as well as the further expansion of business team of specialty production worldwide to support the second business-pillar strategy.

The decrease of financial expense is mainly due to increased interests earned on cash deposits and the increase in currency exchange result in 2017.

1.5. R&D expenditures

Unit: Yuan

Research and development expenditure recorded in expenses of current period	298,604,006
Research and development expenditure capitalized of current period	1,624,189
Total research and development expenditure	300,228,195
Proportion of total research and development expenditure to operating revenue (%)	2.90%
R&D headcount as of December 31 2017	181
% of R&D headcount over total headcount	9%
% of capitalized R&D expenditure over total amount	0.54%

Adisseo has reinforced its R&D resources in China by establishment a new R&D center in Nanjing as well as a new strategic alliance with Sichuan Agriculture University for the purpose to provide timely support and innovation to Nanjing plant as well as more China-market oriented technologies and solutions. During 2017, the incubator (Innov'L@b) has been created to generate a leverage effect and enable Adisseo continuing to increase its annual R&D investment to support its "two-business-pillar" strategy.

1.6. Cash flow

The Adisseo net cash flow from operating activities amounts to RMB 2,513,085,624 compared to RMB 3,053,923,615 last year.

The decrease of net cash flow from operating activities compared to the same period of last year is explained by:

- RMB -659 million (-22%) due to the decrease in Adisseo's sales;
- RMB 118 million (4%) due to changes in the EUR/CNY currency exchange rate.

The economic performance of Adisseo mainly explains the still high level of cash generated. The operating cash flow generated by Adisseo enabled to invest RMB 974,692,179, reimbursed various debt for an amount of RMB 13,073,351 and paid dividends for an amount of RMB 866,995,232.

1.7. Analysis of assets and liabilities

Information of assets and liabilities

Unit: Yuan

Items	As at December 31 , 2017		As at December 31, 2016		% change	Explanation
	Amount	Percentage to total assets (%)	Amount	Percentage to total assets (%)		
Derivative financial assets	19,287,286	0%	11,471,676	0%	68%	Change related to hedging of EUR/USD.
Interest receivable	9,693,743	0%	1,040,703	0%	831%	Interests receivable on cash deposit.
Other receivables	43,080,271	0%	25,869,193	0%	67%	Increase due to insurance compensation of a 2015 losses in Nanjing plant.
Construction in progress	887,324,323	4%	453,360,413	2%	96%	Increase linked to European expansion and A-Dry+ projects.
Long-term prepaid expenses	0	0%	2,367,403	0%	-100%	Amortization of capitalized fees.
Other non-current assets	8,468,000	0%	2,747,272	0%	208%	Miscellaneous prepayments for tangible assets.
Short-term borrowings	0	0%	469,236	0%	-100%	Decrease due to repayments.
Derivative financial liabilities	9,495,399	0%	68,508,557	0%	-86%	Change related to hedging of EUR/USD.

Items	As at December 31 , 2017		As at December 31, 2016		% change	Explanation
	Amount	Percentage to total assets (%)	Amount	Percentage to total assets (%)		
Advances from customers	4,551,000	0%	20,811,000	0%	-78%	Decrease of receipt in advance in China due to less consignment sales.
Wages and benefits payable	690,155,511	3%	443,664,431	2%	56%	Increase linked to employee benefits with maturity less than one year at the end of 2017.
Taxes payable	221,281,764	1%	362,784,968	2%	-39%	Offset effect of French tax on value-added.
Interest payable	8,559,892	0%	5,543,874	0%	54%	Interests accrued.
Dividends payable	154,485,540	1%	104,121,900	1%	48%	Declared dividends higher in 2017.
Long-term employee benefits payable	407,467,115	2%	647,814,349	3%	-37%	Decrease linked to employee benefits with maturity less than one year at the end of 2017.
Provisions	0	0%	29,196,374	0%	-100%	Change of classification of provisions depending on their nature.
Other comprehensive income	(484,132,396)	-2%	(860,732,283)	-4%	44%	Impact of exchange rate EUR/CNY.
Surplus reserve	351,560,696	2%	256,211,737	1%	37%	Allocation of 10% of 2017 net profit of BAC.

2. Overview of 2017 board meeting and shareholders' board meeting

2.1. Attendance of directors at board meetings and general shareholders' meetings

Name of directors	Independent directors	Attendance at Board meetings						Attendance at general shareholders' meetings
		Required attendance at Board meetings in the term of office this year	Attendance in Person	Participation by other communications	Attendance by proxy	Absence	Consecutively Absent From two meetings	Attendance frequency at the general meeting of shareholders
Gérard Deman	N	6	3	3	0	0	N	2
Dazhuang Wang	N	3	2	1	0	0	N	0
Zhigang Hao	N	1	1	0	0	0	N	0
Jean-Marc Dublanc	N	6	3	3	0	0	N	2
Jean Falgoux	Y	6	0	6	0	0	N	2
Lixin Song	Y	6	2	4	0	0	N	2
Zhou Guomin	Y	6	3	3	0	0	N	0
Michael Koenig	N	4	3	1	0	0	N	1

Number of Board meetings held this year	6
Including: Number of meetings held on-site	0
Number of meetings held by other communications	2
Number of meetings held on-site combined with other communications	4

2.2. Board meetings and proposals of each meeting

Boarding meeting	proposals
The 10th meeting of the 6th board of directors	1) Deliberated and passed the proposal on 2016 Annual Report and the Executive Summary; 2) Deliberated and passed the proposal on 2017Annual Budget; 3) Deliberated and passed the proposal on 2016 Annual Accounts; 4) Deliberated and passed the proposal on nominating Michael Koenig as Director Candidate and Member of Special Committee; 5) Deliberated and passed the proposal on 2016 and 2017 day-to-day connected transactions; 6) Deliberated and passed the proposal on the

	Board's Report for FY2016; 7) Listening to Independent Directors' Report for FY2016; 8) Deliberated and passed the proposal on Audit Committee's Report for FY2016; 9) Deliberated and passed the proposal on 2016 Annual Plan of Dividends Distribution; 10) Deliberated and passed the proposal on Self-assessment Report on Internal Control for FY2016 and Audit Report on Internal Control for FY2016; 11) Deliberated and passed the proposal on Special Report of Deposits and Actual Use of Raised Funds for FY2016; 12) Deliberated and passed the proposal on the Special Report on Occupancy of Non-operation Funds and Other Fund Transactions with Connected Parties for FY2016; 13) Deliberated and passed the proposal on the Special Report on the Difference between the Actual Profit and the Profit Forecast for FY2016 of Bluestar Adisseo Nutrition Group Ltd. ; 14) Deliberated and passed the proposal on auditing fees for FY2016; 15) Deliberated and passed the proposal on engagement of KPMG Huazhen LLP as the Company's 2017 annual financial and internal control auditor; 16) Deliberated and passed the proposal on renewal of D&O insurance policy; 17) Deliberated and passed the proposal on the appraisal and remuneration of the directors and executives for FY 2016; 18) Deliberated and passed the proposal on convening the Shareholders' Annual Assembly for FY2016.
The 11th meeting of the 6th board of directors	Deliberated and passed the proposal on 2017 Q1 Report
The 12th meeting of the 6th board of directors	Deliberated and passed the proposal on 2017 H1 Report and the Executive Summary
The 13th meeting of the 6th board of directors	1) Deliberated and passed the proposal on 2017 Q3 Report and the Executive Summary; 2) Deliberated and passed the proposal on

	Changing the Deliberation Procedure of Remuneration & Evaluation Committee; 3) Deliberated and passed the proposal on Appointing Mr. Guomin Zhou and Mr. Michael Koenig as Remuneration & Evaluation Committee Member; 4) Deliberated and passed the proposal on Appointing Mr. Zhigang Hao as Director, Duputy Chairman of the Board, and Member of Strategic Development Committee and Nomination Committee; 5) Deliberated and passed the proposal on Deliberating Financial Risk Management Mechanisms of Bluestar Adisseo Company's Deposit at ChemChina Finance Company and Emergency Plan of Dealing with Financial Risks Related to Bluestar Adisseo Company's Deposit at ChemChina Finance Company; 6) Deliberated and passed the proposal on Convening the 1st Interim General Meeting on 15/12/2017.
The 14th meeting of the 6th board of directors	Deliberated and passed the proposal on BAC's overseas subsidiary bidding for purchasing Tintin 100% equity
The 15th meeting of the 6th board of directors	Deliberated and passed the proposal on Approving BAC's Overseas subsidiary Drakkar Group SA to acquire 100% of the shares of Nutriad Holding B.V.

3. Board of directors' discussion and analysis of the company's future development

3.1. Basic information of the subdivided sectors industry and the company's position in the industry

The animal feed additives industry is exposed to favorable global "megatrends" and is expected to grow significantly over the coming years. This growth is expected to be driven primarily by the industrialization of meat production, global population growth and wealth creation. This should be the case in emerging markets, where consumers' dietary preferences are expected to shift towards protein-rich diets.

Adisseo multi-product portfolio enhances its position with customers and differentiates our product offering from that of our competitors. Since Adisseo supplies a range of nutritional feed additives, it can provide value-added formulation advice to our customers and advise them with respect to their feed additive inclusion rate decisions.

This industry is further characterized by high entry barriers, such as high technological know-how, increasingly stringent regulations to obtain permits and authorizations, compliance with national and regional environmental and health and safety regulations, the ability to source key intermediates and the large capital investments required to develop new methionine and vitamin production capacities.

The chemical process to manufacture methionine requires significant manufacturing expertise and process technology. Access to, or development of, such expertise and technology constitutes a significant barrier to entry in this market. Furthermore, technical and commercial expertise and on-going investment in product and process innovation are critical factors to remain competitive.

Based on industry practice, the initial capital expenditures to build a world-scale, greenfield chemical methionine production facility would require a large amount of capital investment and could require at least four years to permit, plan and construct. Furthermore, access to key intermediates and raw materials used for manufacturing methionine, such as MMP for which there is only a limited number of merchant suppliers, is critical to the establishment of new production facilities.

On the demand side, global methionine continues to grow on a global scale at a rate of 6% per year as shown in the table published by Feedinfo.

	2016	**2017**	**2018**	**2019**
Demand KT	1190	1265	1338	1414
% growth rate	**5.1**	**6.3**	**5.8**	**5.7**
Additional volume	57	75	73	76

On the supply side, methionine supply shortage in 2015 has impacted market prices up. The announced new capacities from competitors have finally come on stream after some delays. In 2016 and 2017, Adisseo faced with a less favorable market environment in the methionine business, after an exceptional 2015 year, as expected.

Negative impacts from price have been partly compensated by Adisseo volumes growth, and raw material prices increase based on a higher Brent level has been partly compensated by rigorous cost management.

By the end of 2017, a temporary rebound has been observed on the market.

- Adisseo's Competitive landscape in each Business:

Methionine

Production capacity in the global methionine market is concentrated, large companies such as Evonik, Adisseo, Novus and Sumitomo Chemical (SCC) are key players. Due to population growth, economic development of emerging economies, and the modernization of the animal husbandry sector, the demand for methionine in the Asia-Pacific area, including China, continues to increase rapidly. China has one of the world's highest production volumes for pork, poultry and livestock. Its animal husbandry sector continues to grow rapidly, which leads to rapid growth in demand for methionine. As the aforementioned key methionine players continue to strengthen their global position currently, they have increased investments in Asia, while domestic companies represented by Ningxia Ziguang keep investing in additional capacity. Zhejiang NHU has entered in the methionine market during the 1st semester of 2017, however, with a nameplate capacity of 50 KT per year, the extra volumes sold into the market during 2017 remained modest in the context of the overall global demand of around 1265 KT. During 2017 CJ sold more product into the market than the previous year. However, the year on year increase was modest and partially absorbed by their growing captive use.

According to a Feedinfo December 2017 report, there have been only minor increases in the volumes of additional capacity brought to the market during the past twelve months and the production of methionine (KT per year) by major players breaks down as follows:



As indicated above, Adisseo is the world's second largest producer of methionine in 2017 with a market share of 27%.

Vitamins

Vitamins are widely used in medicine, food additives and animal feed additives. In recent years, as China's vitamin sector continues to grow, China has become a major producer and exporter of vitamins, and the production technology and market shares for vitamin C, vitamin E, vitamin B2 and vitamin D3 are top-ranked globally. Adisseo's major competitors in the vitamins market mainly include BASF S.E., DSM N.V., Zhejiang NHU and Zhejiang Pharmaceutical. The domestic vitamin A & E production in China is dominated by Zhejiang NHU and Zhejiang Pharmaceuticals Joint Stock Company.

Enzymes

The enzymes market needs extensive research & development, patented technology and capital expenditure for the production. Novozymes, DuPont, Ab Vista, BASF, DSM and Adisseo are the main players.

3.2. Global economy

The main global economies have implemented positive economic policies to stimulate economic growth. Employment rate and inflation are maintained within a reasonable range. The European and U.S. economies have slowly recovered. Several markets, including China, India, are expected to grow.

3.3. Emerging economics present growth opportunities in protein demand

The continuous global growth, particularly that of the emerging economies such as China and India, has driven urbanization and continuous improvement of people's living standards and has promoted per person consumption of high protein foods (poultry, beef, pork, fish etc.).

3.4. Development strategy of the company

Adisseo's businesses are as follows: research, development, production and sale of feed additives for animal nutrition.

The Company has actively implemented its "two-business-pillar" strategy in recent years, i.e. continuous consolidating its leadership in methionine industry, while at the same time accelerating its development in Specialty business.

The Company bases its growth's strategy on four levers:

- Emerging markets footprint: world class methionine production platforms, and a sales network with a focus on high-growth emerging markets and development of specialties

- Innovation: Seven R&D centers focused on several different areas such as analysis, nutrition, formulation, biotechnology, chemical processes, chemistry, formulation and processes to serve 3 axis:
    - Service improvement: an ecosystem of continuous improvement, with direct feedback from customers and third-party experts such as universities and external nutritionists, intimate collaboration with customers to discover their needs, thereby exploring new opportunities
    - Product development: Sustainable operation philosophy and track record of bringing products to market attract co-development from top academic and research institutions. Three major research directions: antibiotics replacement, reduction of harmful outputs, and yield improvement/enhanced cost efficiency
    - Process improvement: Sustainable investment in projects aiming to improve production process and technologies to maintain competitiveness
        - Breakthrough process and continuous improvements of daily methionine production capacity, on top of all the debottlenecking projects, thanks to the involvement of both R&D teams and manufacturing teams
        - Improvement of vitamin A production yield
        - Optimization in Rovabio® production costs
    - To strengthen its position, Adisseo plans to launch a new product every year. Selisseo®, a specialty product based on selenium and a new thermostable enzyme, Advance®, in 2014, a new Non-Starch Polysaccharide enzyme, in 2015 and Alterion®, a new probiotic, in 2016. In 2017, the incubator (Innov'L@b) has been created to generate a leverage effect and we are expecting three new products to be launched in 2018 including Rhodimet® A-Dry+.
- Industrial investments: Adisseo's investment strategy enabled significant gains in methionine market shares in the last 3 years and strong value creation. Adisseo is actively preparing to grow in line with customer demands by combining extensions

and debottlenecking of existing production facilities.

- Methionine
  - Further capacities expansion of the Nanjing and European plants: in 2018, Adisseo will produce 50 KT per year additional capacity of liquid methionine with POLAR project and 9 KT per year capacity of the new product Rhodimet® A-Dry+
  - Approval of the construction of a third platform, with a capacity of 180 KT per year, located in the Nanjing Liuhe Chemical Park, adjacent to the existing Adisseo plant in Nanjing
- Specialty products
  - Reinforcing rumen-protected methionine business to leverage Adisseo's market leadership.
  - Reinforce industrial partnership for specialties development
  - Launching new products at a space of one per year
- Capital expenditures



- M&A and partnerships: To reinforce its core businesses and diversify its portfolio in high growth segments in feed specialties and animal health.
  - Leverage competitive advantages of business partners through partnerships
  - Accelerate growth and create value with acquisitions supported by available financial means given by fortress balance sheet with minimal debt
  - Acquisition of Nutriad announced in December 2017, a global feed additives producer since more than 50 years. This multinational company, headquartered in Dendermonde (Belgium), operates 4 laboratories and 5 plants located in Belgium, Spain, the UK, China and the USA. Nutriad has a solid product range in palatability, mycotoxin management and digestive performance. Next to poultry and swine they are also present in aqua, dairy and cattle. This transaction is part of the Adisseo Group's strategy to become one of the worldwide leaders of specialty additives in animal nutrition. The business generates sales of about USD100 million per year.

Nutriad's product range, the species addressed, and its target markets are highly complementary to Adisseo's and will allow to implement integrated solutions to offer even more value to customers.

Thanks to these levers, Adisseo is confident in its ability to manage its businesses properly, expand product portfolio and reinforce competitiveness and continuous sustainable as well as profitable growth in the market.

3.5. Business plan

Adisseo aims to pursue delivering significant growth with sustainable margins. The figures disclosed below are consolidated figures of BANG and its subsidiaries.

Based on the Profit Forecasting Compensation Agreement signed for the Major Asset Restructuring, Adisseo disclosed a "committed net profit with deduction of non-recurring gains and losses" of EUR 106,506,110 in 2017 (i.e. RMB 812,141,041 using the EUR/CNY average exchange rate of 7.6253).

The net profit with deduction of non-recurring gains and losses amounts to RMB 1,582.57 million which was in excess by RMB 770.43 million in comparison with the committed profit forecast amount for 2017, i.e. RMB 812.14 million as set forth in the Profit Forecasting Compensation Agreement.

Total sales volume is expected to increase across almost all product lines driven by the expected growth in global demand and additional methionine capacities linked to the debottlenecking of existing production plants and the launches of new products.

Developments in Research & Development and Capital expenditures should lead Adisseo to develop its Specialty products and to launch new products.

Adisseo plans for capital expenditure in the upcoming years mainly consist of:

- Further methionine capacities to support sales growth;
- R&D expenditures on innovation of products as well as optimization of manufacturing process;
- Increasing rumen-protected methionine production capacities to leverage Adisseo's technologies;
- Additional enhancement of the Health, Safety and Environment policies.

The Business Plan may not be considered as a guarantee of profitability as committed to the investors.

3.6. C-Sox implementation

Based on the materiality principle, the Company has established a well-rounded internal control policy for those scope-in business or companies and ensure an effective implementation of the policies. The Company has performed adequate self-assessment on the effectiveness of the design as well as the implementation of the whole internal control system and it is confirmed that the Company has reached its target on the internal control and there is no material deficiency identified during the assessment.

For the current reporting period, the Company will issue its self-assessment report separately on internal control based on C-SOX requirement.

.Material 4

Proposal on Board of Supervisors' Report for FY2017

Dear Shareholders,

During the year of 2017, according to *the Company Law of the People's Republic of China* ("the Company Law"), laws, rules, regulatory documents, and *the Articles of Association of Bluestar Adisseo Company* ("AOA"), the Company's board of supervisors supervises the Company's operation and management's performance of duties, supervises the Company's financial matters and issues opinions on distribution of dividends and other matters. Please kindly find attached Board of Supervisors' Report for FY2017 for details.

Please review the above proposal.

Attachment: Board of Supervisors' Report for FY2017

Board of supervisors' report for 2017

1. Meeting of the board of supervisors

Times of meetings held：4

Meetings of the Board of Supervisors	Proposals at the meetings of the Board of Supervisors
The 6th Meeting of the 6th Board of Supervisors	1) Deliberated and passed the proposal on Annual Report and the Executive Summary for FY2016; 2) Deliberated and passed the proposal on Final Annual Accounts for FY2016; 3) Deliberated and passed the proposal on Report of the Board of Supervisors for FY2016; 4) Deliberated and passed the proposal on Annual Plan of Dividends Distribution for FY2016; 5) Deliberated and passed the proposal on Internal Control Self-Appraisal and Audit Reports for FY2016; 6) Deliberated and passed the proposal on Special Report and Review Report on the Deposit and Actual Usage of the Funds Raised for FY2016; 7) Deliberated and passed the proposal on Funds Occupation for non-operating purpose and other funds flow movement with Related Parties for FY2016.

The 7th Meeting of the 6th Board of Supervisors	Deliberated and passed the on 2017 Q1 Report
The 8th Meeting of the 6th Board of Supervisors	Deliberated and passed the proposal on 2017 H1 Report and the Executive Summary
The 9th Meeting of the 6th Board of Supervisors	Deliberated and passed the proposal on 2017 Q3 Report

2. Opinions of the board of supervisors on self-assessment report on internal control for FY2017

In the FY2017, Company has established a fairly mature internal control system which has been effectively implemented. It complies with the “Basic Standards for Internal Control of Enterprises”, the “Complementary Guideline for Internal Control of Enterprises” and relevant requirements of securities regulatory authorities. It fulfills the Company’s actual needs in operation and management, and effectively manages risks in each links. The “Self-assessment Report on Internal Control for FY2017” reflects the overall actual status of the Company’s internal control in a complete, true, objective and accurate way.

3. Independent opinions of board of supervisors on financial inspection of the company

During the reporting period, the Board of Supervisors implemented inspection and supervision over the financial situation of the Company, holding the opinion that the Company has sound financial system, normative operation, effective implementation, reasonable financial structure, and positive financial condition. The 2017 annual financial report of the Company truthfully and objectively reveals the financial condition and operating result of the Company. The audit report with unqualified opinions provided by KPMG Huazhen LLP is objective and fair.

4. Independent opinions of the board of supervisors on proposal of the dividends distribution

The proposal of the dividends distribution of the Company is in line with laws and regulations, and fully reflects shareholders' interests and the Company's condition. There is no damage to the interests of the Company and shareholders.

Material 5

Proposal on 2016 Annual Plan of Dividend Distribution

Dear Shareholders,

The net profit attributable to the shareholders of the Company at the consolidated level for the year ended December 31, 2017 amounted to RMB 1,323,315,773 and the accumulated profits available for distribution at parent company level as at December 31, 2017 amounted to RMB 871,027,986.

To share the operation achievements with all shareholders and for further development of the Company, the board, after fully considering the actual operation status of the Company, propose that: the total share capital of the Company by the date of 31 December 2017 being 2,681,901,273 shares. Company will distribute RMB 1.73(inclusive of tax) per 10 shares in the form of cash dividends to all shareholders. The total amount of the cash dividend to be distributed is RMB 463,968,920.23.

Please review the above proposal.

Material 6

Proposal on Appointment of Auditor and Internal Control Auditor for the Year 2018

Dear Shareholders,

To maintain the continuity of auditing, as proposed by the audit committee of the board, the Company proposes to continue to engage KPMG Huazhen LLP as the Company’s 2018 annual auditor for financial and internal control auditing. The Company also proposes to authorize the board of directors to determine service fees for this engagement, depending on the service items, the workload and other factors.

Please review the above proposal.

Material 7

Proposal on Renewal of D&O Insurance Policy

Dear Shareholders,

To reduce potential risks in the process of due performance of the board members, the supervisors and senior management, the Company is to renew the D&O insurance policy whose annual premium is approximately RMB 292,885 (plus local insurance tax) and the insurance amount not exceeding RMB 127,341,200.

Please review the above proposal.

Material 8

Proposal on Approval of Renewal of Finance Service Agreement between ChemChina Finance Co., Ltd. & Bluestar Adisseo Company

Dear Shareholders,

For the purposes of optimizing financial management, improving efficiency of capital utilization and reducing financing costs and risks, the Bluestar Adisseo Company signed a Financial Services Agreement with ChemChina Finance Co., Ltd. as approved at the annual general meeting of the Bluestar Adisseo Company in 2015. The agreement specified that ChemChina Finance Co., Ltd. shall provide the Bluestar Adisseo Company with such financial services as deposit, settlement and credit for a valid period of 3 years. During the cooperation, ChemChina Finance Co., Ltd. has provided fast and convenient services for the deposit and loaning business of the Bluestar Adisseo Company. Therefore, the Bluestar Adisseo Company has the intention to renew the Financial Services Agreement with ChemChina Finance Co., Ltd. so that the latter company will, within its licensed scope of business, provide the Bluestar Adisseo Company with such financial services as deposit, settlement and credit.

I. Basic Information on ChemChina Finance Co., Ltd.

Jointly founded by China National Chemical Corporation (ChemChina) and its member companies, ChemChina Finance Co., Ltd. is a non-banking financial institution that provides financial services for ChemChina member companies. With the approval by China Banking Regulatory Commission for its establishment, ChemChina Finance Co., Ltd. was officially opened for business since July 2009. Its legal representatives are: Feng Yimin, with a registered capital of RMB 841.225 million; and the business license registration number is 91110000100019622W. In this company, ChemChina holds 49.41%, China National BlueStar (Group) Co., Ltd. holds 26.88%, China Haohua Chemical Group Co., Ltd. holds 15.81%, and China National Agrochemical Co., Ltd. holds 7.9% of the stake.

The main businesses ChemChina Finance Co., Ltd. has been licensed to engage in are as follows: accounting and financial consultation, credit authentication for member units; assisting member units to collect and pay amounts for transactions; provision of approved insurance agency services; guarantee services for members units; loans and investment on behalf of member units; acceptance and discounting of bills for member units; internal transfer and settlement between member units and development of plans for corresponding settlement; acceptance of deposits of member units; loans and finance leases for member units; inter-bank borrowing; underwriting of corporate bonds for member units; and investment in fixed-income securities.

The total assets of ChemChina Finance Co., Ltd. amounted to RMB 12.672 billion by 31st Dec 2017 and its operating income reached RMB 347.39 million.

II. Association with the BlueStar Adisseo Company

ChemChina Finance Co., Ltd. is a subsidiary of ChemChina, which is the parent company of China National BlueStar (Group) Co., Ltd., the controlling shareholder of BlueStar Adisseo Company, and also serves as the actual controller of BlueStar Adisseo Company. ChemChina Finance Co., Ltd. and the BlueStar Adisseo Company are all subject to the same actual controller, which is a case that accords to the stipulation in Paragraph (2), Article 10.1.3 of the Rules Governing the Listing of Stocks on the Shanghai Stock Exchange.

III. Principles and Main Contents of the Financial Services Agreement

The Financial Services Agreement that the BlueStar Adisseo Company intends to sign with ChemChina Finance Co., Ltd. stipulates that ChemChina Finance Co., Ltd. shall provide relevant financial services to the BlueStar Adisseo Company and that the agreement shall be valid for 3 years.

Principles for the signing of the agreement are as follows:

Both parties to the agreement shall regard each other as an important partner and give full play to their advantages in the respective fields to achieve common development through business cooperation and to maximize the interests of both parties. Both parties shall cooperate in the principles of equality, voluntariness, complementary advantages, mutual benefits, common development and win-win outcome

Main contents of the agreement:

ChemChina Finance Co., Ltd. shall provide the BlueStar Adisseo Company with the following financial services:

Deposit. The BlueStar Adisseo Company will open a deposit account at ChemChina Finance Co., Ltd. for its funds in the principle of free deposit and withdrawal. The deposit may take such forms as demand deposit, term deposit, notice deposit and agreement-based deposit. The interest rate of ChemChina Finance Co., Ltd. for the deposit service provided to the BlueStar Adisseo Company shall not be lower than the deposit interest rate for the same type of deposits as enacted by the People's Bank of China in the same period, or lower than the deposit interest rate of China's major commercial banks, or lower than the deposit interest rate of other ChemChina member units at ChemChina Finance Co., Ltd. in the same period.

Settlement. In line with the BlueStar Adisseo Company's directives, ChemChina Finance Co., Ltd. shall provide the BlueStar Adisseo Company with payment and collection services (including cash sweep service) and other settlement-related supporting services; and ChemChina Finance Co., Ltd. shall provide the above settlement services free of charge for the BlueStar Adisseo Company.

Credit. In accordance with relevant laws and regulations of the country, ChemChina Finance Co., Ltd. shall provide comprehensive credit services for the BlueStar Adisseo Company based on the latter's needs for operation and development. The BlueStar Adisseo Company may use the comprehensive credit line provided by ChemChina Finance Co., Ltd. to deal with loans, acceptance and discounting of bills, guarantees and other forms of financial accommodation businesses, and ChemChina Finance Co., Ltd. shall make its best effort to meet the needs of the BlueStar Adisseo Company within the scope of its own financial capability. ChemChina Finance Co., Ltd. shall undertake to provide the BlueStar Adisseo Company with preferential lending rates which are not higher than the interest rate of the same type received by the BlueStar Adisseo Company from other domestic financial institutions during the same period.

Other financial services. ChemChina Finance Co., Ltd. shall, in accordance with the instructions and requirements of the BlueStar Adisseo Company, provide the latter with other financial services within the scope of its businesses and shall consult and enter into an independent agreement before the former's provision of such financial services; and the fees charged by ChemChina Finance Co., Ltd. for the provision of these financial services shall not be higher than those charged by major financial institutions in China for the same services.

IV. Risk Control

ChemChina Finance Co., Ltd. shall ensure safe operation of the capital settlement network, ensure the security of funds, and control the risk of assets and liabilities so as to meet the payment needs of the BlueStar Adisseo Company.

In the event that any occurrence on the ChemChina Finance Co., Ltd.'s part that may endanger the security of the BlueStar Adisseo Company's deposits or pose a material safety risk to the BlueStar Adisseo Company's deposits, ChemChina Finance Co., Ltd. shall notify the BlueStar Adisseo Company in writing within 2 working days and take due measures to avoid consequent losses or the aggravation of the consequences.

The BlueStar Adisseo Company will implement strict internal control so as to prevent and control capital risks of the BlueStar Adisseo Company's deposits at ChemChina Finance Co., Ltd..

V. Purposes and Impact of the Agreement on the BlueStar Adisseo Company

The transaction between the associated parties is conducive to the BlueStar Adisseo Company in optimizing its financial management, improving its efficiency of capital utilization, and reducing the financing costs and risks.

Please review the above proposal.

Attachment ： Financial Service Agreement

Financial Service AgreementBetween and By

Bluestar Adisseo Company and ChemChina Finance Co., Ltd.

Party A: Bluestar Adisseo Company

Legal Representative: Jean-Marc Dublanc

Position: CEO

Postal Address: No. 9 Beitucheng West Road, Chaoyang District, Beijing

Zip Code: 100029

Tel.: 010-61958799

Fax: 010-61958805

Party B: ChemChina Finance Co., Ltd.

Legal Representative: FENG Yimin

Post: Chairman

Postal Address: No. 62 Beisihuan West Road, Haidian District, Beijing

Zip Code: 100080

Tel.: 010-82677978

Fax: 010-82677453

Whereas,

1. Party A is a joint-stock limited company duly established and lawfully existing, which was listed for trading at Shanghai Stock Exchange on April 20, 2000. In order to optimize its financial management, raise capital utilization efficiency, and lower financing costs and financing risks, Party A plans to cooperate with Party B, and to obtain related financial services from Party B.

2. Party B, as a financial company duly organized and lawfully existing, was established

with the approval of China Banking Regulatory Commission, and started business operation formally on July 2, 2009. With powerful capital strength and abundant financial service experience, Party B is willing to cooperate with Party A and provide related financial services for Party A.

In order to regulate clearly the rights and obligations of Party A and Party B, the both parties hereto conclude and enter into the *Financial Service Agreement* (the "Agreement") after reaching consensus through equal and friendly negotiation in accordance with the *General Principles of the Civil Law of the People's Republic of China*, the *Contract Law of the People's Republic of China* and other related laws and regulations based on the principles of equality and transparency will as well as in good faith.

I. Cooperation Principles

1. Party A and Party B agree to cooperate with each other, and Party B provides related financial services for Party A according to the stipulations herein.

2. Party A and Party B shall treat each other as the important partner, give full play to their own advantages in their own fields to achieve the common development and maximum mutual benefits through business cooperation.

3. The cooperation between Party A and Party B is non-exclusive. Party A has the right to decide whether it needs and accepts the service of Party B at its own discretion by combining with its own interests, and it's also entitled to independently select other financial service providers.

4. Party A and Party B agree to establish a periodic meeting system at executive level and establish an effective communication mechanism, in order to communicate and discuss business and conduct cooperation in a timely manner.

5. Party A and Party B shall cooperate with each other under the Agreement in line with the principles of equality and free will, with mutually complementary advantages, mutual benefit and reciprocity, for common development and double win.

II. **Service Scope**

As agreed, Party B shall provide Party A with the following financial services:

1. Deposit Service:

(1) Party A shall open a deposit account with Party B, and deposit its working capital into the said deposit account in line with the principle of free deposit and withdrawal. The form of deposit may be current deposit, term deposit, notice deposit, agreement deposit, etc.

(2) The deposit interest rate of the deposit services provided by Party B for Party A shall not be lower than that of similar deposits in the same period uniformly issued by the People's Bank of China, and that of similar deposits in the same period of China's domestic major commercial banks, and that of similar deposits in Party B of the other member enterprises of China National Chemical Corporation in the same period;

(3) The sum of the year-end balance and interest of Party A's deposits in Party B shall not exceed 5% of Party A's total assets audited in the latest fiscal year, and shall not exceed 50% of the total ending monetary resources audited in the latest fiscal year;

(4) The capital deposited by Party A at Party B shall be totally deposited by Party B at commercial banks established with China's formal approval, including China Construction Bank, Bank of China, Bank of Communications, and Party B may also use the same in line with the principle of prudence according to the regulations of laws;

(5) Where Party B fails to withdraw full-amount deposit to Party A on time, Party A shall have the right to terminate the Agreement, and may offset Party A's loans from Party B with the deposit payable by Party B to Party A;

(6) Where Party A suffers economic losses due to Party B's contractual defaults, Party B shall make full-amount compensation therein, and meanwhile, Party A shall have the right to terminate the Agreement.

2. Settlement Service:

(1) Party B shall, upon Party A's command, provide Party A with payment service and collection service, as well as other auxiliary services related to settlement business;

(2) Party B shall provide Party A with the abovementioned settlement services for free;

(3) Party B shall ensure the safe operation of funds settlement system, guarantee the security of the capital, control asset-liability risks, and satisfy Party A's payment demands.

3. Credit Service:

(1) In line with the related laws and regulations in China, Party B shall provide integrated credit services for Party A upon the demands of Party A’s operation and development. Party A may use the integrated credit line provided by Party B to handle loans, bill acceptance, bill discounting, guarantee, and other forms of financing businesses. Party B shall endeavor to satisfy Party A’s demands preferentially within the scope of its own financial capacity;

(2) Party B promises that it shall provide Party A with a preferential loan interest rate, lower than that of the same level in the same period obtained by Party A from other domestic financial institutions;

(3) Both parties hereto shall conclude and enter into a separate agreement for the concrete matters concerning credit service.

4. Other Financial Services:

(1) Party B shall, according to Party A’s instructions and requirements, provide other financial services within its business scope for Party A. Before Party B provides other financial services for Party A, both parties hereto shall negotiate and conclude a separate agreement additionally;

(2) The fees to be collected by Party B for other financial services provided shall not be higher than those collected by China's major financial institutions for similar services.

III. Commitments of Party B

1. Party B shall provide good-quality and high-efficiency financial services for Party A according to the stipulations herein, and design customerized service programs for Party A upon Party A’s actual demands.

2. Party B shall, after opening online banking services, design and install online banking services for Party A upon Party A’s demand, in order to realize safe, convenient and efficient funds settlement.

3. Party B shall send a written notification to Party A within two working days, and adopt measures to avoid the occurrence or further expansion of losses, if any of the following circumstances appears:

(1) Major events occur to Party B, including but not limited to, run on banks, failure to pay large-amount debts due, occurrence of a large amount of overdue loans or guarantee advances, involvement of directors or senior management personnel into criminal cases, etc.;

(2) Matters like important organizational changes, serious operating risks, which affect or will probably affect Party B’s normal operation;

(3) The loans of Party B's stockholders from Party B cannot be repaid after being overdue for more than 6 months;

(4) Any of Party B’s asset-liability ratio indexes violates the regulations of the *Measures for the Administration of Finance Companies of Enterprise Groups*;

(5) Party B falls under serious circumstances such as being imposed administrative penalty, ordered to rectify by regulatory government bodies such as China Banking Regulatory Commission;

(6) Other matters which will probably cause serious potential safety hazards to Party A's deposit.

IV. Confidentiality

1. Party A and Party B unanimously agree to assume the obligation to keep confidential the other party’s business secrets and other secrets known due to the implementation of the Agreement. Without the other party’s consent, neither party hereto shall disclose such secrets to any third party or use the same for any unjust purpose, unless otherwise specified in related laws, rules, and normative documents of regulatory departments.

2. Unless otherwise specified herein, Party A and Party B shall fulfill the confidentiality obligation hereunder until related information materials are disclosed by the other party, or have actually been disclosed or entered into public fields.

V. Execution, Alteration and Rescission of the Agreement

1. The Agreement shall take effect after being executed by both parties hereto and going through related legal deliberation procedures with its valid term of three years.

2. The Agreement may be altered and rescinded after that both parties hereto reach negotiation-based consensus and written agreement, before which the clauses of the Agreement shall still be effective.

3. Where some clauses herein are invalid or non-executable, the validity of the other clauses herein shall not be affected.

VI. Settlement of Disputes

1. Both parties hereto shall solve through negotiation all the disputes, dissensions or claims arising from or related to the signing and implementation of the Agreement.

2. In case negotiation fails, either party hereto may submit the dispute(s) to Beijing Arbitration Committee for arbitration according to its then effective arbitration rules. The result of arbitration shall be final, binding on both parties hereto.

VII. Miscellaneous

The Agreement is made in two counterparts, and each party hereto holds one with the same legal force.

(To Leave Blank)

(The page is only for the signature page of the *Financial Service Agreement* between and by Bluestar Adisseo Comapny and ChemChina Finance Co., Ltd.)

Party A: Bluestar Adisseo Company (Seal)

Legal Representative / Authorized Representative: Jean-Marc Dublanc

Date of Signature:

Party B: ChemChina Finance Co., Ltd. (Seal)

Legal Representative / Authorized Representative: FENG Yimin (Seal)

Date of Signature: